Infertility, Female

10
Pipeline Programs
8
Companies
15
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
2
4
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
CFAPhase 41 trial
Pre-treatment with rLHPhase 31 trial
Active Trials
NCT03741699CompletedEst. May 2024
NCT03755973Completed24Est. May 2023
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
7 programs
1
1
3
FE 999049Phase 31 trial
FE 999049 + GnRH agonistPhase 31 trial
Follitropin deltaPhase 31 trial
Degarelix mid-luteal, 2.5 mgPhase 21 trial
A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mLPhase 11 trial
+2 more programs
Active Trials
NCT04814940Withdrawn0Est. Sep 2023
NCT04654039Completed728Est. Oct 2023
NCT04902131Completed95Est. Aug 2022
+4 more trials
Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
2 programs
2
Autologous PRP intra ovarian infusionPhase 2/31 trial
Autologous Platelet Rich PlasmaPhase 2/31 trial
Active Trials
NCT03916978RecruitingEst. Jul 2026
NCT03951194UnknownEst. Jul 2025
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1012DPhase 11 trial
Active Trials
NCT06864793Active Not RecruitingEst. Apr 2026
ConvaTec
ConvaTecNJ - Bridgewater
1 program
IVF with the Neria™ Guard Subcutaneous CatheterN/A1 trial
Active Trials
NCT05505474UnknownEst. Dec 2024
Genomics
GenomicsUK - Oxford
1 program
Timelapse incubation and PGTN/A1 trial
Active Trials
NCT06419127Enrolling By Invitation2,000Est. Jun 2033
Gedeon Richter
Gedeon RichterHungary - Budapest
1 program
ULIPRISTAL ACETATEN/A1 trial
Active Trials
NCT03349190Completed127Est. Jan 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.CFA
Ferring PharmaceuticalsFE 999049
Ferring PharmaceuticalsFE 999049 + GnRH agonist
Merck & Co.Pre-treatment with rLH
Ferring PharmaceuticalsFollitropin delta
Genesis TherapeuticsAutologous Platelet Rich Plasma
Genesis TherapeuticsAutologous PRP intra ovarian infusion
Ferring PharmaceuticalsDegarelix mid-luteal, 2.5 mg
Qilu PharmaceuticalQL1012D
Ferring PharmaceuticalsA MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL
GenomicsTimelapse incubation and PGT
ConvaTecIVF with the Neria™ Guard Subcutaneous Catheter
Ferring PharmaceuticalsMENOPUR Cohort
Ferring PharmaceuticalsOther: Non intervention
Gedeon RichterULIPRISTAL ACETATE

Clinical Trials (15)

Total enrollment: 4,385 patients across 15 trials

NCT03755973Merck & Co.CFA

Effect of Different Ovarian Stimulation Protocols on Endometrial Receptivity

Start: Jan 2020Est. completion: May 202324 patients
Phase 4Completed
NCT06173869Ferring PharmaceuticalsFE 999049

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

Start: Mar 2024Est. completion: May 2025301 patients
Phase 3Completed
NCT03809429Ferring PharmaceuticalsFE 999049 + GnRH agonist

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

Start: Apr 2019Est. completion: Feb 2022437 patients
Phase 3Completed
NCT03741699Merck & Co.Pre-treatment with rLH

Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH)

Start: Feb 2019Est. completion: May 2024
Phase 3Completed
NCT03738618Ferring PharmaceuticalsFollitropin delta

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

Start: Oct 2018Est. completion: Dec 2020588 patients
Phase 3Completed
NCT03951194Genesis TherapeuticsAutologous Platelet Rich Plasma

Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women

Start: Jun 2019Est. completion: Jul 2025
Phase 2/3Unknown
NCT03916978Genesis TherapeuticsAutologous PRP intra ovarian infusion

Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women

Start: May 2019Est. completion: Jul 2026
Phase 2/3Recruiting
NCT00434122Ferring PharmaceuticalsDegarelix mid-luteal, 2.5 mg

Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix

Start: Mar 2007Est. completion: Dec 200785 patients
Phase 2Completed
NCT06864793Qilu PharmaceuticalQL1012D

Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers

Start: Apr 2025Est. completion: Apr 2026
Phase 1Active Not Recruiting
NCT04902131Ferring PharmaceuticalsA MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL

A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women

Start: Nov 2021Est. completion: Aug 202295 patients
Phase 1Completed
NCT06419127GenomicsTimelapse incubation and PGT

Embryo Assessment Utilizing Timelapse Imaging in Conjunction With Preimplantation Genetic Testing for Aneuploidy With Next Generation Sequencing

Start: Jan 2025Est. completion: Jun 20332,000 patients
N/AEnrolling By Invitation
NCT05505474ConvaTecIVF with the Neria™ Guard Subcutaneous Catheter

Use of a Subcutaneous Catheter for Controlled Ovarian Stimulation

Start: Nov 2023Est. completion: Dec 2024
N/AUnknown
NCT04814940Ferring PharmaceuticalsMENOPUR Cohort

Retrospective Analysis of Real-world Data From Medical Records on the Use of MENOPUR for Infertility Treatment

Start: Sep 2022Est. completion: Sep 20230
N/AWithdrawn
NCT04654039Ferring PharmaceuticalsOther: Non intervention

Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)

Start: Oct 2020Est. completion: Oct 2023728 patients
N/ACompleted
NCT03349190Gedeon RichterULIPRISTAL ACETATE

Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques

Start: Dec 2017Est. completion: Jan 2019127 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 4,385 patients
8 companies competing in this space